Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 124

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 124
---
 less abuse liability stemmed from the fact
that based on their research, MEAI was shown to release less dopamine and more serotonin when compared to MDMA, and dopamine releases
have been shown in drug abuse literature to create more abuse liability than serotonin releases. Based on the findings of the study that
MEAI and MDMA produce similar effects, we believe that if approved for therapeutic use by the FDA and comparable regulatory bodies, MEAI
will be able to be used for similar forms of pharmaceutical therapy for mental disorders that MDMA is currently being tested in clinical
trials for, such as for treating AUD and PTSD. Furthermore, if the author’s assertion that MEAI has less of a tendency to be abused
is accepted by the FDA and comparable regulatory bodies, MEAI may be able to offer a more appealing alternative to MDMA for these pharmaceutical
treatments.

Limitations of this study include that it was conducted
only on 29 targets and not on full panels of all the central nervous system receptors. In addition, only affinity values for each compound
at the specific receptors were measured without measuring functional activity, meaning that the study only examined whether MEAI binds
to a specific receptor but did not determine receptor activation due to MEAI binding.

Evaluation of the Efficacy of MEAI in Binge
Alcohol Consumption in Mice.

An efficacy study mimicking voluntary alcohol consumption
was conducted in female C57BL/6 mice to assess the ability of MEAI to alter ethanol intake. The study was completed by Pharmaseed, Israel’s
largest good laboratory certified CRO specializing in translational and regenerative studies. The principle of the study is based on intermittent
access to 20% alcohol in a two-bottle choice (IA2BC) model in mice: one bottle contains water, and the other bottle contains a 20% ethanol
solution. In total, the mice were exposed to 20% ethanol 24 hours a day, three days a week, for seven-eight weeks (amounting to 21-22
alcohol consumption days). Alcohol consumption was measured after each 24-hour period of alcohol exposure. Following five weeks of intermittent
access to 20% alcohol, the mice were allocated to nine groups of nine mice according to their alcohol consumption and were then administered
MEAI (20 to 100 mg/kg/day) or vehicle for 13 days. Overall the target screening and the efficacy animal model were performed in order
to characterize the mechanism of action of MEAI. The data illustrated that ME